|
Variable
|
Coefficient (95% CI)
|
p-value⊥
|
Conditional R2
|
Interactions
|
|---|
|
DAS28-CRP
|
−0.22 (−0.32, −0.11)
|
<0.001
|
0.614
|
HAQ*
|
|
HAQ
|
−1.06 (−1.27, −0.84)
|
<0.001
|
0.610
|
-
|
|
Pain (VAS)
|
−0.14 (−0.19, −0.09)
|
<0.001
|
0.603
|
-
|
|
Fatigue (VAS)
|
−0.15 (−0.19, −0.10)
|
<0.001
|
0.606
|
-
|
|
PGA (VAS)
|
−0.16 (−0.21, −0.11)
|
<0.001
|
0.594
|
-
|
|
SF-36 MCS
|
0.40 (0.29, 0.50)
|
<0.001
|
0.607
|
-
|
|
IPQ-R illness coherence
|
0.12 (0.09, 0.15)
|
<0.001
|
0.617
|
-
|
|
IPQ-R treatment control
|
0.16 (0.12, 0.20)
|
<0.001
|
0.619
|
-
|
|
IPQ-R personal control
|
0.09 (0.06, 0.11)
|
<0.001
|
0.608
|
-
|
|
IPQ-R consequences
|
−0.17 (−0.19, −0.15)
|
<0.001
|
0.690
|
-
|
|
IPQ-R emotional representations
|
−0.11 (−0.12, −0.09)
|
<0.001
|
0.634
|
-
|
|
RAQoL
|
−0.11 (−0.12, −0.09)
|
<0.001
|
0.640
|
HAQ**
|
|
PhGA (VAS)
|
−0.12 (−0.19, −0.04)
|
0.002
|
0.613
|
-
|
|
TJC28
|
−0.01 (−0.06, 0.03)
|
0.590
|
0.594
|
-
|
|
SJC28
|
0.01 (−0.04, 0.07)
|
0.630
|
0.594
|
-
|
|
CRP
|
0.00 (−0.01, 0.01)
|
0.550
|
0.594
|
-
|
|
ESR
|
0.00 (0.00, 0.01)
|
0.320
|
0.597
|
-
|
- ⊥Bonferroni correction for multiple comparisons was applied, setting the significance level at p < 0.003
- *Interaction (ß = 0.24; 95% CI = 0.12–0.36; p < 0.001) implies that the additional effect of DAS28-CRP on self-efficacy (SE) decreases with increasing HAQ
- **Interaction (ß = 0.05; 95% CI = 0.03–0.08; p < 0.001) implies that the additional effect of RAQoL on SE decreases with increasing HAQ
- ASES Arthritis Self-Efficacy Scale, DAS28 Disease Activity Score in 28 joints, HAQ Health Assessment Questionnaire, VAS visual analogue scale, PGA patient’s global assessment of disease activity, SF-36 MCS Short-Form 36 mental component score, IPQ-R Revised Illness Perception Questionnaire, PhGA physician’s global assessment of disease activity, TJC28 tender joint count in 28 joints, SJC28 swollen joint count in 28 joints, CRP C-reactive protein, ESR erythrocyte sedimentation rate
